Healthcare -
Biotechnology - NASDAQ - US
$ 5.22
0.967 %
$ 465 M
Market Cap
-6.52
P/E
1. INTRINSIC VALUE
Balance Sheet
aTyr Pharma, Inc.
| Current Assets | 82 M |
| Cash & Short-Term Investments | 72.1 M |
| Receivables | 1.74 M |
| Other Current Assets | 8.09 M |
| Non-Current Assets | 14.9 M |
| Long-Term Investments | 2.95 M |
| PP&E | 11.9 M |
| Other Non-Current Assets | 66 K |
| Current Liabilities | 15 M |
| Accounts Payable | 4.32 M |
| Short-Term Debt | 1.25 M |
| Other Current Liabilities | 9.39 M |
| Non-Current Liabilities | 12 M |
| Long-Term Debt | 12 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
aTyr Pharma, Inc.
| Revenue | 235 K |
| Cost Of Revenue | 1.54 M |
| Gross Profit | -1.3 M |
| Operating Expenses | 68.1 M |
| Operating Income | -67.9 M |
| Other Expenses | -3.89 M |
| Net Income | -64 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
aTyr Pharma, Inc.
| Net Income | -64 M |
| Depreciation & Amortization | 1.54 M |
| Capital Expenditures | -65 K |
| Stock-Based Compensation | 2.99 M |
| Change in Working Capital | -6.92 M |
| Others | -8.69 M |
| Free Cash Flow | -69.2 M |
Wall Street Analysts Price Targets
aTyr Pharma, Inc.
ATYR has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ATYR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
aTyr Pharma, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
8.14 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
15 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
185 K USD 1
9-12 MONTHS
7. News
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses.
globenewswire.com
- 4 weeks ago
aTyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.
globenewswire.com
- 1 month ago
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity.
globenewswire.com
- 1 month ago
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 36,200 shares of aTyr's common stock, each with an exercise price of $3.00 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on May 15, 2025, the effective date of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.
globenewswire.com
- 1 month ago
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
Preclinical data demonstrate ATYR0101's unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit.
globenewswire.com
- 1 month ago
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025.
globenewswire.com
- 1 month ago
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present a poster featuring preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2 (NRP2), at the American Association for Cancer Research (AACR) Annual Meeting 2025, which is being held April 25 – 30, 2025, in Chicago, IL. “Aggressive cancers like glioblastoma multiforme (GBM) continue to show drug resistance, and the efficacy of current immunotherapies may be limited due to immunosuppressive myeloid cells in the tumor microenvironment that contribute to drug resistance.
globenewswire.com
- 2 months ago
aTyr Pharma to Participate in April Investor Conferences
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025. Details of the conferences appear below: Conference: Jones Healthcare and Technology Innovation Conference Date: April 8 – 9, 2025Location: Las Vegas, NVFormat: 1x1 Investor Meetings Conference: Piper Sandler Spring Biopharma Symposium Date: April 17, 2025Location: Boston, MAFormat: 1x1 Investor Meetings For more information on how to register, please contact your Jones or Piper Sandler representative.
globenewswire.com
- 2 months ago
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors approved on March 21, 2025 an aggregate of three grants to three employees of nonstatutory stock options to purchase an aggregate of 43,800 shares of aTyr's common stock with a weighted-average exercise price of $3.69 per share, which is equal to the weighted-average closing price of aTyr's common stock on the Nasdaq Capital Market on the effective dates of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.
globenewswire.com
- 3 months ago
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise.
globenewswire.com
- 3 months ago
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
zacks.com
- 3 months ago
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating
aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows promise in reducing fibrosis without immunosuppression, with recent safety data and a peer-reviewed publication bolstering confidence in its efficacy. Institutional ownership has surged to nearly 80%, indicating strong institutional confidence despite the inherent risks associated with earlier trial failures.
seekingalpha.com
- 3 months ago
8. Profile
Summary
aTyr Pharma, Inc. ATYR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 465 M
Dividend Yield
0.00%
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Contact
10240 Sorrento Valley Road, San Diego, CA, 92121
https://www.atyrpharma.com
IPO
Date
None
Employees
56
Officers
Ms. Dalia R. Rayes M.B.A.
Head of Commercial, Global Efzofitimod Franchise
Dr. Leslie Nangle Ph.D.
Vice President of Research
Ms. Ashlee Dunston
Director of Investor Relations & Corporate Communications
Mr. Peter Villiger
Vice President of Corporate Development
Dr. Sanjay S. Shukla M.D., M.S.
President, Chief Executive Officer & Director
Ms. Jill M. Broadfoot CPA
Chief Financial Officer
Dr. Jayant Aphale MBA, Ph.D.
Vice President of Technical Operations
Ms. Nancy E. Denyes Krueger J.D.
General Counsel & Corporate Secretary
Ms. Danielle Campbell
Vice President of Human Resource